Palladio Biosciences is a technology company.
Palladio Biosciences has raised $20.0M across 1 funding round.
Palladio Biosciences has raised $20.0M in total across 1 funding round.
Palladio Biosciences has raised $20.0M in total across 1 funding round.
Palladio Biosciences's investors include Red Tree Venture Capital.
Palladio Biosciences is a privately-held, clinical-stage biopharmaceutical company focused on developing transformative medicines for orphan kidney diseases.[1][2] Its lead candidate, lixivaptan, targets autosomal dominant polycystic kidney disease (ADPKD), a condition with limited treatment options, by acting as a potent, selective vasopressin V2 receptor antagonist.[1] The company serves patients with rare kidney disorders, addressing unmet needs through innovative therapies, and has raised $20 million in Series B financing to advance its pipeline.[1]
Headquartered in Horsham, Pennsylvania, Palladio operates with a small team (<25 employees) and revenue under $5 million, emphasizing clinical progress like studies on lixivaptan in ADPKD patients intolerant to alternatives such as tolvaptan.[1]
Palladio Biosciences was formed to advance lixivaptan, in-licensed from a partner committed to unmet medical needs in kidney diseases.[1][5] The company emerged from efforts to repurpose this vasopressin V2 antagonist for ADPKD, building on prior research while addressing gaps in tolerability and efficacy of existing treatments.[1] Key early milestones include completing a $20 million Series B financing and presenting clinical data, such as ePosters at the American Society of Nephrology on lixivaptan's use in challenging ADPKD cases.[1] Backed by investors like Medicxi, Palladio has evolved from inception to clinical-stage development, humanizing its mission through patient-focused innovation in orphan diseases.[1][6]
Palladio rides the wave of precision medicine for rare diseases, capitalizing on growing regulatory incentives like orphan drug designations that accelerate approvals and provide market exclusivity. Timing aligns with rising ADPKD awareness and vasopressin antagonist validation (e.g., tolvaptan's approval), yet Palladio differentiates via better patient tolerance amid a biotech surge in nephrology.[1] Market forces favoring it include increasing venture funding for clinical-stage biopharma ($20M Series B) and demand for kidney-specific therapies as chronic kidney disease prevalence climbs globally.[1] It influences the ecosystem by advancing under-served orphan segments, potentially paving the way for broader vasopressin-based innovations in renal care.[1][5]
Palladio's path forward hinges on lixivaptan trial readouts and potential Phase 3 advancement, with partnerships like Medicxi enabling scale-up.[1][6] Trends like AI-driven drug repurposing and orphan incentives will propel its momentum, possibly leading to partnerships or acquisition by larger pharma players eyeing nephrology gaps. Its influence may expand by proving selective antagonists' viability, reshaping ADPKD standards and inspiring kidney-focused biotechs—reinforcing its role as a nimble innovator in a high-need niche.[1][2]
Palladio Biosciences has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series B in September 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2020 | $20.0M Series B | Red Tree Venture Capital |